Article: Circassia Announces Acquisition of Organ Transplant Anti-Rejection Technology.

Expands Circassia's Pipeline of Immune Control Products

Complements Circassia's Anti-Allergy Technology

OXFORD, England, July 12 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, today announced the acquisition of a novel anti-rejection technology for use in organ transplantation. Circassia acquired the proprietary technology, known as ToleroTrans, from The University of Birmingham in the UK for an undisclosed upfront sum, plus future milestone payments and royalties on product sales. Scientifically, the ToleroTrans approach mirrors that of Circassia's existing anti-allergy technology, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!